I recently shared quick impressions and opinions of meeting with the Diabetes Technology Society. I’ll begin now with a rumination that kindled slowly; then offer a roundup of other recent activities.
Concerning my passivity at DTS. Though I traveled as an NSF sponsored investigator, I didn’t hunt and gather evidence that shores up my business model. I didn’t follow the I-Corps script for customer discovery and afterwards I wondered why. Without realizing it, I may have become recalcitrant towards the empiricism of lean startup. There I was, schmoozing and kibitzing in Bethesda, getting out of the proverbial building. But instead of probing stakeholders about problems and needs, I was learning their science and taking time to ponder and reflect. Ideation and reflection are among the missing pieces of lean puzzles. Lean technique is more reactive or opportunistic than inquisitive and creative. So maybe I was reverting to form at DTS after my summertime plunge in the turbulent Mines of Moria-Newark.
Concerning revenue streams. At my poster session in Bethesda I told a diabetes drug company that it doesn’t want what Humaginarium is making. You invest in sickness, I said, but Humaginarium is an investment in wellness. They told me I was mistaken. A few days later a marketing advisor told me I was wrong. A few days after that a business mentor told me I was stupid. The net? I must restore health care companies to my customer segmentation! Why? Because two pharmaceutical executives liked the idea of Humaginarium. That counts as evidence in a lean startup. Yet I don’t want to do it! I already view health care companies as revenue streams because they are potential sponsors and advertisers. I don’t view them as customers because that, honestly, is not what they are. Think about it. They sell products and services to clinicians who care for patients, but how does that qualify them as my customers? They don’t even qualify as my business partners because their job has little if anything to do with promoting health literacy. They sell stuff to doctors but they don’t empower patients. In this light the advice I got feels unhelpful and distracting (not unusual when a startup is incubating).
Now looking beyond DTS, I recently wrote three challenge grants for support of our prototype project Diabetes Agonistes. All three were (ironically) sponsored by health care companies: big pharma, a provider system, and a payer organization. I’m not sanguine about making even the first cut in these pitches, but it’s good practice and I hope to collect a bit of useful feedback from potential sponsors and advertisers about the role of Humaginarium in the health care ecosystem. I learned yesterday about a fourth challenge grant that resonates because the corporate sponsor claims it wants to disrupt the health care industry. I’ll write that grant as well.
After returning from Bethesda I interviewed two consultants, one in Indiana and another in Michigan. They advise startups that want to apply for SBIR funding. SBIR has been a goal of Humaginarium for about a year now. We were prevented from making a December 2018 submission by nuisance factors in I-Corps. However these consultant interviews were encouraging and a good reset. Right afterwards a third consultant was recommended to me, this one in Illinois. On the basis of these inputs, Humaginarium may apply for Phase 1 SBIR at least twice in 2019: to NSF in June and NIH in September. There’s also a chance that we’ll discover other sources of government funding and foundations that make program-related investments in health education and wellness.
Still looking ahead, after the Thanksgiving holiday I’m going to visit somebody I’ve wanted to meet for years: a research scientist at UChicago Medicine who founded a studio making games for health. Though her focus is pedagogy and mine is andragogy, I am so looking forward to meeting and will write about it in a future blog. She and the medical director of LevelEx are in my gallery of local heroes.
Speaking of university, over the past few days Humaginarium became the subject of a practicum for business school students at Northern Illinois University. If enough students sign up, starting in January 2019 they and a faculty advisor will research and draft marketing and commercialization plans that bridge the abyss between entertainment and health. That bridge building is fundamentally my mission, so I am very excited about this project. I’ll ask the class to study the commercialization model of Professor Scott Meadow at the University of Chicago, which is the best thing of its kind I have seen and way better than lean templates that are more familiar among startups.
Last but certainly not least in this meandering roundup, I interviewed a quant named Richard Cross who is not looking for work but who easily gets what I’m trying to create (bless him). Our 30 minutes together were full of ideation and reflection. My kind of guy. He offered to connect me with people who can plot the kind of mathematical model that I want for consumers exploring the human body in Humaginarium. A model I can use to generate real-time scenarios of adventure, complementing the real-time scenarios of physiology that I already have with HumMod. My vision for world building in this fantasy platform is biology that truly mimics and yet improves nature. When consumers roam the miracle known as the human body, I want them to experience what exists under their skin as well as what could happen there with a braver and more skillful self at the controls. A digital engine that turns our teeny weeny Diabetes Agonistes into gobsmacking cool video games that keep people up at night jailing the baddies of chronic illness in their own bodies.